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ARF Promotes MDM2 Degradation and Stabilizes p53:
ARF-INK4a Locus Deletion Impairs Both
the Rb and p53 Tumor Suppression Pathways
cell cycle and escape from cell cycle arrest/apoptosis
following DNA damage may be two critical events that
a cell requires to become cancerous.
The regulation of p53 and pRB pathways are distinctly
different. Many genotoxic stresses, particularly DNA
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tions of p53 are common in human cancer, the molecu-University of North Carolina at Chapel Hill
lar pathways regulating p53 abundance by individualChapel Hill, North Carolina 27599-3280
signals have yet to be elucidated fully; however, many
appear to regulate p53 posttranscriptionally, such as
through governance of p53's ubiquitin-mediated prote-Summary
olysis (Ko and Prives, 1996). p53's tumor suppression
activity is in fact directly opposed by the human papillo-The INK4a-ARF locus encodes two unrelated proteins
mavirus E6 oncoprotein through its targeting p53 forthat both function in tumor suppression. p16INK4a binds
degradation (Scheffner et al., 1990, 1993). Similarly,to and inhibits the activity of CDK4 and CDK6, and
MDM2-induced p53 degradation appears to play a criti-ARF arrests the cell cycle in a p53-dependent manner.
cal role in regulating the level of p53 protein (Haupt etWe show here that ARF binds to MDM2 and promotes
al., 1997; Kubbutat et al., 1997). mdm2, a proto-onco-the rapid degradation of MDM2. This interaction is
gene that is amplified in 30%±40% of sarcomas (Olinermediated by the exon 1b±encoded N-terminal domain
et al., 1992), encodes a protein that can bind and inacti-of ARF and a C-terminal region of MDM2. ARF-pro-
vate the transcriptional activity of p53, resulting in abro-moted MDM2 degradation is associated with MDM2
gation of p53's antiproliferative and apoptotic effectsmodification and concurrent p53 stabilization and ac-
(Momand et al., 1992; Oliner et al., 1992, 1993). Mostcumulation. The functional consequence of ARF-regu-
sarcomas with mdm2 amplification retain the wild-typelated p53 levels via MDM2 proteolysis is evidenced by
p53 gene and protein (Leach et al., 1993), suggestingthe ability of ectopically expressed ARF to restore a
that amplification of mdm2 may be biologically equiva-p53-imposed G1 cell cycle arrest that is otherwise
lent to mutational inactivation of p53. Deletion of theabrogated by MDM2. Thus, deletion of the ARF-INK4a
mdm2 gene in mice results in early embryonic lethality,locus simultaneously impairs both the INK4a±cyclin
which can be rescued by the simultaneous deletion of
D/CDK4-RB and the ARF-MDM2-p53 pathways.
p53, indicating that p53 is the major target of MDM2 in
development (Jones et al., 1995; Luna et al., 1995). Un-
Introduction like p53, where regulation of activity appears to be pri-
marily at the level of protein abundance, the growth-
The development of human cancers is frequently associ- suppressive function of pRB is primarily regulated by
ated with the inactivation of two major tumor suppres- cell cycle±dependent phosphorylations (Weinberg, 1995).
sion pathways represented by the retinoblastoma pro- Following mitosis, pRB emerges in a hypophosphory-
tein, pRB, and by p53 (Weinberg, 1995; Sherr, 1996; lated form, which becomes hyperphosphorylatedduring
Levine, 1997). Via distinct mechanisms, pRB and p53 mid to late G1 phase and then maintains this hyperphos-
play critical roles in transducing a variety of growth in- phorylated state throughout the remainder of the cell
hibitory signals to the cell cycle control machinery, and cycle. Hypophosphorylated pRB binds and controls a
their inactivation may lead to uncontrolled cell prolifera- number of cellular transcription factors such as the
tion and a predisposition to neoplasia. pRB exerts most, members of the E2F family, while hyperphosphorylated
if not all, of its growth suppressive effects in the first pRB no longer interacts with these proteins. The kinases
two-thirds of the G1 phase of the cell cycle by binding that have been strongly implicated as responsible for
transcription factors required for initiating and pro- pRB phosphorylation are the cyclin-dependent kinases
gressing through S phase. When bound by pRB, these (CDKs), particularly the cyclin D±dependent kinases
transcription factors are converted from transcriptional CDK4 and CDK6 (Ewen et al., 1993; Kato et al., 1993).
activators to transcriptional repressors, thereby pre- The activity of CDK4/6 is inhibited by association with
venting cells from exiting the G1 phase of the cell cycle CDK inhibitors (Sherr and Roberts, 1995). A specific
(Weinberg, 1995). On the other hand, p53 is itself a tran- inhibitor of CDK4/6, p16INK4a, is mutated, deleted, or
scription factor that activates the expression of genes down-regulated by promoter methylation in many hu-
that induce a G1 cell cycle arrest or apoptosis in re- man tumors. In human cancers, the estimated frequency
sponse to DNA damage (Gottlieb and Oren, 1996; Ko of genetic alteration involving the p16 locus is believed
and Prives,1996, Levine, 1997). The concurrent inactiva- to be second only to alteration of p53 (Hunter and Pines,
tion of these two pathways in human cancer occurs 1994; Sherr, 1996). The extraordinarily high frequency
frequently and argues that unscheduled entry into the of genetic alteration of the INK4a locus in human cancer
may stem from its unique genomic organization. In addi-
tion to INK4a (Serrano et al., 1993), this locus encodes‖ To whom correspondence should be addressed.
# These authors contributed equally to this work. a second protein, ARF, whose enforced expression, like
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that of INK4a, also induces cell cycle arrest and whose
disruption in mice results in development of multiple
tumor types early in life (Quelle et al., 1995; Kamijo et
al., 1997). The ARF-INK4a locus contains two unique
first exons, designated 1a and 1b, which are spliced
into common exons 2 and 3 (Duro et al., 1995; Mao et
al., 1995; Quelle et al., 1995; Stone et al., 1995). While the
exon 1a±exon 2±exon 3 transcript encodes the CDK4/6-
specific inhibitor INK4a, the exon 1b±exon 2±exon 3
transcript through an alternative reading frame encodes
ARF, which bears no homology to INK4a at the amino
acid level (Quelle et al., 1995). As such, homozygous
deletion of the locus, which occurs frequently in a variety
of human cancers, causes a loss of both the INK4a gene
and the ARF gene, spawning complications in determin-
ing the individual contributions of the two genes in tumor
suppression (Serrano et al., 1996; Kamijo et al., 1997).
While analysis of both familial and sporadic cancer-
associated mutations have indicated that INK4a, not
ARF, is preferentially being targeted (Quelle et al., 1997),
mice lacking p19ARF but retaining intact p16INK4a de-
velop multiple tumors (Kamijo et al., 1997), indicating
that ARF, like INK4a, is also a bona fide tumor suppres-
sor. Unlike INK4a, which binds to and inhibits the activity
of CDK4/6 (Serrano et al., 1993; Xiong et al., 1993a),
ARF does not induce cell cycle arrest by acting directly
as a CDK inhibitor (Quelle et al., 1995), and there is no
evidence that ARF exerts its growth-inhibitory effect
through the pRB pathway; instead, it requires the pres-
ence of wild-type p53 for induction of a G1 cell cycle
arrest. Established cell lines that lack p53 or have p53
mutations are resistant to growth arrest by ectopic ex-
pression of ARF (Kamijo et al., 1997), suggesting that
ARF may act upstream of p53. We report here that hu-
Figure 1. Human ARF Binds MDM2
man ARF protein binds to and promotes the rapid degra-
(A) HF7c yeast cells werecotransformed with the indicated plasmidsdation of MDM2, leading to stabilization and accumula-
(key) and plated onto media lacking leucine and tryptophan (2LW)
tion of p53. Our results reveal an ARF-MDM2-p53 tumor to verify the expression of both bait (Leu1) and prey (Trp1) plasmids;
suppression pathway that parallels the INK4a±cyclin onto a 2LW plate for assaying b-galactosidase activity (data not
shown); or onto media lacking leucine, tryptophan, and histidineD/CDK4-pRB pathway. Deletions of the INK4a-ARF lo-
(2LWH) for examining the interaction between bait and prey pro-cus therefore effectively impair both of these two major
teins.tumor suppression pathways.
(B) Epitope-tagged (HA or myc) human ARF and MDM2 were in vitro
translated inthe presence of [35S]methionine, eitherseparately (lanes
1±8, 11, 13±15, 18, and 19) or together (lanes 9, 10, 12, 16, 17, 20,
Results and 21). IVT products either directly underwent SDS-PAGE (input,
lanes 13±17) or were mixed to allow complex formation and then
immunoprecipitated with the indicated antibodies prior to electro-Human ARF Binds to MDM2
phoresis.We used the yeast two-hybrid system to search for pro-
(C) HeLa±tet off cells were cotransfected with vectors expressingteins capable of physically interacting with human ARF
human mdm2 and either HA-tagged INK4a (HA-INK4a), HA-tagged
(Fields and Song, 1989). A 0.4 kb cDNA fragment encod- ARF (HA-ARF), or the parental pTRE vector. Two days after transfec-
ing the132 amino acid residues of full-length human ARF tion, cell lysates were prepared and immunoprecipitated with affin-
was fused in-frame with the yeast Gal4 DNA±binding ity-purified antibodies to ARF (a-ARF), to HA (a-HA), or to HA anti-
sera blocked with HA peptide (a-HA 1 HA). Immunoprecipitatesdomain (Gal4-BD). The resulting vector was cotrans-
were separated by SDS-PAGE and immunoblotted with MDM2 an-formed into yeast HF7c cells with a human HeLa two-
tisera.hybrid cDNA library (see Experimental Procedures). Of
(D) Mdm2 immunoprecipitates (lanes 1±3) from cells transfected as
an estimated 2.1 3 106 transformants screened, one in (C) were electrophoretically separated prior to immunoblotting
clone was obtained that proliferated on media lacking with an anti-ARF antibody. Lane 4 contains cell lysate from COS7
histidine and was positive for b-galactosidase staining cells transfected with human HA-ARF sequences to confirm the
mobility of HA-ARF in the HeLa cell lysate.(Figure 1A and data not shown). Direct DNA sequencing
of the rescued plasmid revealed that this clone encodes
a truncated human MDM2 containing the C-terminal 284 the growth of HF7c yeast cells in the presence of the
amino acids (beginning with residue 208), suggesting histidine synthesis inhibitor 3-amino-1, 2, 3-triazole (3-
that the ARF protein may interact with a C-terminal do- AT, data not shown). ARF was unable to interact with
main of MDM2. The interaction between ARF and MDM2 the GAL4 DNA activation domain (negative control) ex-
pressed from the parental vector pGAD-GH. Conversely,protein appeared to be relatively strong as indicated by
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human INK4a fused with Gal4-BD was able to interact
with CDK4 but not with MDM2 (Figure 1A).
We confirmed ARF-MDM2 binding in a cell-free sys-
tem using in vitro translated proteins (Figure 1B). Two
versions of the ARF protein with different N-terminal
epitope tags, one containing a myc epitope (myc-ARF)
and one containing an HA epitope (influenza hemagluti-
nin, HA-ARF), were in vitro translated using reticulocyte
lysate in the presence of [35S]methionine, either sepa-
rately or together with full-length human MDM2. Mix-
tures containing [35S]-labeled ARF and MDM2 proteins
were immunoprecipitated with either an affinity-purified
polyclonal antibody specific to ARF or with monoclonal
antibodies to myc or MDM2, and the precipitates were
resolved by SDS-PAGE. Human MDM2 protein, pro-
duced either by in vitro translation (Figure 1B) or ectopic
expression in mammalian cells (see below), resolved by
SDS-PAGE into two discrete bands. The exact nature
and origin of these two forms of MDM2 protein have
not been determined. No detectable differences were
observed between these two forms throughout the
study. Neither the myc nor the ARF antibody cross-
reacted with MDM2, and likewise the MDM2 antibody
did not cross-react with ARF (Figure 1B, lanes 1±6).
MDM2 protein was coprecipitated with ARF by both the
anti-ARF (lanes 7±10) and the anti-myc antibodies (lanes
11 and 12) whether ARF and MDM2 proteins were co-
translated (lanes 9, 10, and 12) or mixed after separate Figure 2. ARF Binds to MDM2 through an Exon 1b±Encoded
N-Terminal Domaintranslation (lanes 7, 8, and 11). Reciprocally, the ARF
protein was detected in the same set of mixtures when Myc epitope±tagged full-length ARF (myc-ARF), the exon 1b±
encoded N-terminal domain (myc-ARF[N]), and the exon 2-3±immunoprecipitated with two different antibodies spe-
encoded C-terminal domain [myc-ARF(C)] of human ARF were incific to MDM2; one recognizes an epitope correspond-
vitro translated and labeled with [35S] and then mixed with similarlying to amino acids 154±167 (lanes 18±21), and one rec-
produced full-length human MDM2. Mixtures were immunoprecipi-
ognizes an epitope between residues 3±22 (data not tated with indicated antibodies followed by SDS-PAGE and autora-
shown). diography. U2OS cells were transfected with the indicated plasmids
containing the mutant ARF proteins described above in addition toTo further confirm complex formation between ARF
CD20. Forty-eight hours later transfected cells were analyzed forand MDM2 proteins, HeLa tet-off cells were transfected
cell cycle position after staining with propidium iodide following 10with plasmids directing the expression of human MDM2
hr of nocodazole treatment. Schematic representation of the dele-(pCMV-MDM2) together with either HA epitope±tagged
tion constructs and their ability to bind to MDM2 and cause a G1
ARF (pTRE-HA-ARF), INK4a (pTRE-HA-INK4a), or the arrest are provided.
parental vector (pTRE). Expression of similar amounts
of MDM2 protein in all the transfections was confirmed
exon 1b, which encodes 64 amino acids residues. Theby immunoblotting of total cell lysates with anti-MDM2
exon 1b domain by itself can induce a G1 cell cycleantibody (Figure 1C, lanes 1±3). Protein complexes were
arrest with a potency similar to if not higher than thatalso examined by sequential immunoprecipitation and
of full-length ARF, and deletion of exon 1b resulted inimmunoblotting (IP-Western). When total cell lysates
a mutant ARF that was unable to arrest the cell cyclewere immunoprecipitated with an antibody specific to
(Quelle et al., 1997). To identify the domains within ARFeither ARF or HA, MDM2 protein was detected in the
that are required for binding to MDM2, we constructedlysate derived from cells cotransfected with MDM2 and
two ARF mutants, one containing the N-terminal 64ARF (lanes 10 and 11) but not in cells cotransfected with
amino acids encoded by exon 1b and the other lackingMDM2 and either the parental pTRE vector (lanes 4±6)
the exon 1b encoded N-terminal 64 amino acids, andor INK4a (lanes 7±9). Coprecipitation of MDM2 with HA-
tested their ability to bind MDM2. Because our anti-ARF was efficiently blocked by the preincubation of the
ARF C-terminal peptide antibody does not recognizeanti-HA antibody with a competing antigenic HA peptide
the N-terminal domain, we added a myc epitope tag to(lane 12). Reciprocally, the ARF, but not the INK4a, pro-
the amino terminus of both mutants (myc-ARF[N] andtein was detected in anti-MDM2 immunoprecipitates de-
myc-ARF[C], respectively). In vitro translated, [35S]-rived from cells cotransfected with MDM2 (Figure 1D).
labeled wild-type or mutant ARF protein was mixed with
similarly produced full-length MDM2 protein and recip-
rocally immunoprecipitated with antibodies to eitherARF Interacts with MDM2 via an Exon
1b±Encoded Domain MDM2 or the myc epitope (Figure 2, top). We first con-
firmed the expected effects on the cell cycle by theThe ARF and INK4a genes share common exons 2 and
3, but each contains a unique exon 1. Deletion analysis ectopic expression of each ARF construct. As previously
observed, expression of the exon 1b±encoded domainhas mapped the cell cycle arrest activity of ARF within
Cell
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p53. Formation of a ternary ARF±MDM2±p53 complex
suggests that if ARF regulates MDM2 function, it may
not involve simple competitive disruption of MDM2's
association with p53. Therefore, we examined the pos-
sibility that ARF affects the stability of MDM2. HeLa
cells were transfected with plasmid vectors expressing
MDM2 with or without ARF or mdm2 and p53 with and
without ARF, and the half-life of MDM2 was determined
by pulse-chase labeling (Figure 4A). Ectopically ex-
pressed MDM2 alone has a half-life of approximately
90 min in HeLa cells. Coexpression of MDM2 with ARF
dramatically reduced the half-life of MDM2 protein to
approximately 30 min regardless of the presence or ab-
sence of p53 (Figure 4B). To determine whether the ARF-
dependent shortened half-life of MDM2 decreased the
steady-state level of MDM2 protein, total cell lysate de-
rived from transfected HeLa cells was separated by
Figure 3. Human ARF, MDM2, and p53 Form a Ternary Complex
SDS-PAGE, transferred to a nitrocellulose filter, and ap-
HeLa cells were transiently transfected with combinations of plas-
propriate sections were immunoblotted with antibodiesmids directing expression of human ARF, MDM2, and/or p53. Two
specific to each transfected protein. Cotransfection ofdays after transfection, the cells were metabolically labeled with
MDM2 with ARF (Figure 4C, lane 4), but not with INK4a[35S]methionine, and the lysates were immunoprecipitated with anti-
bodies to ARF, MDM2, and p53. Immunoprecipitated proteins were (lane 5), significantly reduced the steady-state level of
separated by SDS-PAGE and visualized by autoradiography. MDM2protein. The apparent constant steady-state level
of p53 protein resulting from the transfections in this
is sufficient to cause a G1 cell cycle arrest with similar experiment was by design. By transfecting with high
potency to that caused by the full-length ARF (Figure 2, levels of p53 expressing vector, we could determine
bottom). While the C-terminal domain mutant did not whether the change in MDM2 protein abundance medi-
exhibit any detectable interaction with MDM2 (lanes 7 ated by ARF is p53 protein level independent.
and 10), the N-terminal domain of ARF binds to MDM2 Of potential significance is a distinct mobility shift of
with similar affinity as full-length ARF (compare lanes 5 the MDM2 protein upon coexpression with ARF protein
and 6, 8 and 9), indicating that the N-terminal 64 amino (Figure 3, compare lanes 10 with 11 and 12; Figure 4A,
acids encoded by exon 1b are both required and suffi- compare lanes 1±6 with lanes 7±12; lanes 13±18 with
cient for binding to MDM2. lanes 19±24). We have not determined the nature of this
ARF-promoted MDM2 modification and whether this
ARF Forms a Ternary Complex modification regulates the stability of MDM2.
with MDM2 and p53
MDM2 binds p53 through an N-terminal domain (Chen
Degradation of MDM2 by ARF Leads to p53et al., 1993; Oliner et al., 1993). The observation that
Stabilization and AccumulationARF binds to a C-terminal domain of MDM2 prompted
MDM2 promotes the rapid degradation of p53 (Hauptus to test whether ARF can form a ternary complex
et al. 1997, Kubbutat et al., 1997). To test whether ARF-with MDM2 and p53. HeLa cells were transfected with
promoted MDM2 degradation leads to p53 stabilizationcombinations of plasmid vectors expressing ARF, MDM2,
and accumulation, we determined the half-life of p53 inand/or p53. Transfected cells were metabolically labeled
cells cotransfected with either MDM2 or MDM2 plusARFwith [35S]methionine, and the cell lysates were immuno-
(Figure 5A). The half-life of p53 ectopically expressedprecipitated with antibodies specific to each of the indi-
in HeLa cells is approximately 3 hr, shorter than thevidual proteins. All three antibodies specifically recog-
estimated 7 hr half-life determined in Saos-2 cells (Kub-nized their target proteins (Figure 3, lanes 3, 10, and 14)
butat et al., 1997). We presume this change in p53's half-and did not cross-react with the other two proteins
life is due to an E6-activated p53-degradation activity(lanes 4, 9, and 17). Both binary ARF±MDM2 (lanes 5
present in HeLa cells. Ectopic expression of p53 appar-and 11) and MDM2±p53 (lanes 10 and 16) complexes
ently overides theE6-mediated p53 degradation activity,can be readily precipitated using antibodies to either
as evidenced by the accumulation of p53 (see below).relevant protein. In cells triply transfected with plasmids
This is consistent with previous observations that treat-expressing all three proteins, an ARF±MDM2±p53 ter-
ment of HPV-positive cells with genotoxic agents, suchnary complex was formed as determined by the pres-
as UV and mitomycin, resulted in an increase of p53ence of ARF in anti-p53 immunoprecipitates (lane 18)
protein and its transactivating activity (e.g., Butz et al.,and reciprocally p53 in anti-ARF precipitates (lane 6). In
1995). Cotransfection of a p53 expressing plasmid withthe absence of MDM2, ARF and p53 association was
a plasmid expressing MDM2 reduced the half-life of p53not detectable (lanes 3 and 15), indicating that the ARF-
from 3 hr to about 60 min. Triple transfection of plasmidsp53 association is bridged by MDM2.
expressing p53, MDM2, and ARF completely restored
the half-life of p53 to 3 hr (Figure 5B). To test whetherARF Promotes the Rapid Degradation of MDM2
inhibition of MDM2-promoted p53 destabilization byThe main function of MDM2 is to regulate p53 by com-
plexing with and promoting the rapid degradation of ARF results in p53 accumulation, the steady-state level
ARF Regulates MDM2
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Figure 4. ARF Promotes Rapid Degradation
of MDM2
(A) HeLa cells were transfected with the indi-
cated plasmids. Twenty-four hours after trans-
fection, cells were pulsed with [35S]methio-
nine for 2 hr, then chased with fresh ªcoldº
media for the indicated length of time, and
the lysates were immunoprecipitated with an
antibody specific to MDM2. MDM2 precipi-
tates were separated by SDS-PAGE and visu-
alized by autoradiography.
(B) The amount of labeled MDM2 protein at
each time point was quantitated on a Phos-
phoImager (Molecular Dynamics, ImageQuant
software version 3.3), normalized relative to
the amount of radiolabeled MDM2 present in
cells following the 0 min chase, and plotted
versus chase time for HeLa cells transfected
with the indicated plasmids.
(C) Lysates of HeLa cells transiently trans-
fected with combinations of plasmids ex-
pressingp53, MDM2, HA-tagged human ARF,
and INK4a were electrophoretically sepa-
rated and immunoblotted with antibodies
recognizing mdm2, p53, or the HA epitope.
of p53 was determined by IP-Western (Figure 5C). HeLa We also examined the stability of ARF by pulse-chase
labeling of HeLa cells transfected with ARF sequences.cells express nearly undetectable levels of endogenous
p53 (lane 4). Cotransfection of MDM2 with p53 reduced Transfected ARF has a half-life of approximately 90 min
in HeLa cells similar to that of MDM2 (data not shown),p53 to nearly background levels (compare lanes 2 and
4). Transfection of ARF together with p53 and MDM2 suggesting the possibility that ARF like MDM2 may be
regulated by proteolysis. It is interesting to note thatrestored p53 steady-state levels to a level similar to that
seen in singly transfected cells (compare lanes 1 and unlike ARF, INK4a is a protein with a long half-life (with
little change over a 3 hr half-life experiment) (Parry et3), indicating that ARF blocks MDM2-promoted p53
degradation. We purposely used 5:5:1 ratio of ARF, al., 1995), further underscoring the distinction between
these two proteins. The half-life of ARF protein did notMDM2, and p53 expressing plasmids in this experiment
to ensure that adequate levels of MDM2 and ARF would change significantly in the presence of either ectopically
expressed MDM2 or MDM2 plus p53 (data not shown).be present to affect p53 levels.
Figure 5. ARF Abrogates MDM2-Promoted
p53 Degradation
(A) HeLa cells were transiently transfected
with p53, p53 and mdm2; or p53, mdm2,
and ARF expression plasmids as indicated.
Twenty-four hours after transfection, cells
were pulsed with [35S]methionine for 2 hr and
then chased for the indicated length of time.
Cell lysates were immunoprecipitated with an
antibody specific to p53. p53 immunoprecipi-
tates were separated electrophoretically by
SDS-PAGE and visualized by autoradiog-
raphy.
(B) The amount of labeled p53 protein at each
time point was quantitated on a Phospho-
Imager (Molecular Dynamics, ImageQuant soft-
ware version 3.3), normalized relative to the
amount of radiolabeled p53 present in cells
following the 0 min chase, and plotted versus
chase time for HeLa cells transfected with the
indicated plasmids.
(C) HeLa cells were transiently transfected
with plasmids expressing human p53 alone
(lane 1), p53 and MDM2 (lane 2), or p53,
MDM2, and ARF (lane 3). Lane 4 represents
untransfected HeLa cells. Each individual
transfected cell lysate was immunoprecipi-
tated with p53 antisera prior to electropho-
retic separation, immobilization of the pro-
teins, and immunoblotting with p53 antisera.
Cell
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ARF Reverses MDM2's Abrogation
of p53-Mediated Growth Arrest
Forced overexpression of MDM2 is able to completely
abolish the G1 cell cycle arrest caused by p53 (Chen et
al., 1994; 1996). Given the effects of ARF expression on
the stability of MDM2 and p53 proteins, we sought to
determine if ARF could reverse MDM2's abrogation of
p53-induced cell cycle arrest. The human U2OS cell line,
a human osteosarcoma line that contains wild-type p53,
was transfected with combinations of plasmids driving
expression of p53, MDM2, and ARF. Cells were simulta-
neously transfected with the cell surface marker CD20
to allow selection of transfected cells. Following trans-
fection, a portion of the cells was analyzed for cell cycle
distribution by flow cytometric analysis of CD20-positive
cells, while another portion was analyzed for the expres-
sion of individual proteins. Consistent with previous re-
ports (Chen et al., 1996), ectopically expressed p53
caused cell cycle arrest in G1, and this p53-mediated
G1 arrest was overcome by MDM2 (Figure 6A, 6B). When
ARF was cotransfected into cells overexpressing p53
and MDM2, it restored the G1 arrest to the level seen
in cells singularly transfected by p53. Analysis of protein
expression by immunoblotting revealed that p53 trans-
fection resulted in an increase in the steady-state level
of endogenous p21 (Figure 6C). The increase in p21 is
most likely due to transcriptional activation by p53, since
cotransfection of MDM2 resulted in a decrease in p21
protein levels to that seen in cells transfected with vector
alone. Ectopic expression of ARF in addition to p53 and
MDM2 restored the p53-induced p21 protein levels and
was associated with a decrease in the steady-state lev-
els of the MDM2 protein similar to that observed in HeLa
Figure 6. Human ARF Restores MDM2-Abrogated, p53-Mediatedcells (Figure 4C). We noticed that the steady-state level
Cell Cycle Arrestof p53 was not significantly changed in cells transfected
(A) U2OS cells were transiently transfected with the CD20 cell sur-with MDM2 or in cells transfected with MDM2 and ARF
face marker and pCI-neo; p53; p53 and mdm2; or p53, mdm2, andin addition to p53 (Figure 6C, lanes 2±4). This data is
human ARF. The fraction of transfected cells (as determined by
consistent with the notion that MDM2 can affect p53's expression of CD20) in the G1 phase of the cell cycle was compared
transactivating activity without altering p53 protein lev- between the transfections.
els, through repression of p53 mediated transcription by (B) The G1 cell cycle arrest caused by p53 was standardized to
100% (the actual increase in the G1 fraction caused by p53 waseither masking the activity domain of p53 or by directly
14%). Cotransfection of mdm2 with p53 completely reversed theinterfering with the basal transcriptional machinery (Mo-
G1 arrest seen with the transfection of p53 alone. Expression ofmand et al., 1992, Thut et al., 1997)
human ARF in addition to p53 and mdm2 restored the G1 cell cycleAlthough we only determined the steady-state level of
arrest seen with p53 alone. A minimum of 4,000 CD20-positive cells
each protein, not their half-lives, this result is consistent were analyzed for each transfection.
with our finding in HeLa cells that ARF can decrease (C) Lysates from cells transfected with the indicated plasmids, in
the steady-state levels of MDM2 by promoting its degra- addition to CD20, were electrophoretically separated before immu-
noblotting with a-MDM2, a-p53, or a-p21.dation. The simplest explanation for the cancellation of
MDM2-imposed abrogation of p53-mediated arrest by
ARF is that the rapid degradation of MDM2 by ARF leads
1997), suggesting that ARF may act upstream of p53.to p53 stabilization and accumulation.
Here, we present evidence that the ARF protein can
stabilize the p53 protein by binding to and promotingDiscussion
the degradation of MDM2, providing a molecular mecha-
nism for ARF function in cell cycle control and tumorThe ARF-INK4a locus encodes two unrelated proteins
suppression.both capable of inducing cell cycle arrest when overex-
Destabilization of MDM2 by ARF precluded detectionpressed (Serrano et al., 1993; Quelle et al., 1995). The
of in vivo complex formation between these two pro-INK4a protein inhibits cell cycle progression by binding
teins. However, four different assays all indicate thatto and inhibiting the activity of cyclin D±dependent ki-
this interaction is direct and not bridged by anothernases 4 and 6 (CDK4 and CDK6), thereby maintaining
molecule: the yeast two-hybrid assay, reconstitution inthe pRB protein in its growth suppressive, hypophos-
insect cells through baculovirus expression, an in vitrophorylated state. The ARF protein, when ectopically ex-
binding assay, and in vivo transfection of mammalianpressed, causes cell cycle arrest incells containing wild-
type p53 but not in p53-deficient cells (Kamijo et al., cells (see also Pomerantz et al., 1998 [this issue of Cell]).
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The binding domains for the ARF±MDM2 interaction activity). In the absence of E6, E6AP does not bind to
p53 (Huibregtse et al., 1991; Scheffner et al., 1993). Onhave been mapped to the N-terminal and C-terminal
regions of ARF and MDM2, respectively. Ectopic expres- the other hand, MDM2 promotion of p53 degradation
requires direct binding of MDM2 to p53 and is indepen-sion of the exon 1b±encoded N-terminal region of murine
ARF has been previously shown to be both necessary dent of both E6 and E6AP (Haupt et al., 1997; Kubbutat
et al., 1997). This suggests that E6 and MDM2 utilizeand sufficient to cause cell cycle arrest (Quelle et al.,
1997). Our finding that ARF binds MDM2 through exon different mechanismsto selectively target p53 for degra-
dation and that ARF stabilizes p53 independently of1b±encoded sequences domain is entirely consistent
with and further supports the biological activity of this E6. Third, if the increase in MDM2 degradation by ARF
required or was enhanced by E6, it would suggest thatdomain in arresting the cell cycle. MDM2 binds to p53
via its N-terminal domain, and deletion of the C-terminal E6 itself is associated with an activity that promotes
MDM2 degradation. In essence, that would lead to anportion has little effect on the binding of MDM2 to p53
(Chen et al., 1993; Oliner et al., 1993), indicating that the E6-promoted p53 stabilization, rather than degradation
as has been observed. Finally, transfection of U2OShighly conserved central and C-terminal regions may
encode a separable function(s). The C-terminal 284 resi- cells, a human osteosarcoma cell line that does not
contain E6, by p53 resulted in a cell cycle arrest thatdues of MDM2 is sufficient to interact with ARF (Figure
1A), assigning a possible function to this ARF-binding was abrogated by cotransfection of p53 and MDM2. The
p53-mediated arrest was restored by triple transfectionregion as important in regulation of MDM2 stability and
abundance. with p53,MDM2, and ARF (Figure 6). In these transfected
cells, ectopic expression of p53 resulted in an increaseThe functional significance of the ARF±MDM2 interac-
tion is not fullyunderstood at present.One consequence in p21, cotransfection of p53 with MDM2 reduced p21
to background level, and triple transfection with ARFof the ARF±MDM2 interaction is promotion of MDM2
protein degradation. The half-life of ectopically ex- restores p21 back to the level seen in p53±singly trans-
fected cells. Although we only determined the steady-pressed MDM2 protein in HeLa cells of approximately
90 min was reduced to 30 min by cotransfection of an state level of each protein, not their half-lives, this result
supports and is consistent with the finding made in HeLaequal amount of plasmid vector expressing ARF (Figure
4A). Reduction of the half-life of MDM2 by ARF is associ- cells that ARF promotes MDM2 degradation. Our re-
sults, however, do not exclude the possibility that ARFated with a decrease in the steady-state level of MDM2
protein to nearly background level in transfected cells, may regulate MDM2 through other mechanisms in addi-
tion to promoting its degradation. Intriguingly, ARF,indicating the potency of ARF in promoting the degrada-
tion of MDM2. Consequently, the p53 protein, which is MDM2, and p53 can form a stable ternary complex, likely
bridged by MDM2 via its two separate domains, whichdestabilized by overexpression of MDM2, is stabilized
by the coexpression of ARF, restoring the p53 level to can independently interact with p53 and ARF (Figure 3).
It is conceivable that ARF may be able to ablate MDM2'sthat seen in singly transfected cells (Figure 5C). We
further note that ARF itself is a short-lived protein with functional repression of p53-mediated transcription (Thut
et al., 1997).its estimated half-life being approximately 90 min in
transfected HeLa cells, suggesting the possibility that Normally, p53 protein is kept at a low concentration
in a cell by its relatively short half-life. Several types ofthe abundance of ARF may also be subjected to regula-
tion at the level of protein stability. cellular stresses, particularly DNA damage, result in a
rapid increase in p53 concentration. The mechanism byThe biochemical mechanism underlying ARF-pro-
moted MDM2 degradation, as in the case of MDM2- which these genotoxic stresses induces p53 accumula-
tion is not well understood but likely involves lengthen-promoted p53 degradation, remains to be elucidated.
Whether the degradation of MDM2, like that of p53 (Maki ing p53's half-life. The major function of MDM2 in vivo
appears to be regulation of p53, as evidenced by theet al. 1996), is also mediated by an ubiquitin-dependent
pathway is not known. ARF-promoted MDM2 degrada- rescue of embryonic lethality of mdm2-deficient mice
by codeletion of p53 (Jones et al., 1995; Luna et al.,tion could be indirect (e.g., by regulating the modifica-
tion of MDM2 and p53) or direct (e.g., by acting as an 1995). The p53 protein issignificantly destabilized by the
overexpression of MDM2 (Haupt et al., 1997; Kubbutat etE3-like ubiquitin ligase to target MDM2, analogous to
HPV E6±promoted p53 degradation). A possible compli- al., 1997) (Figure 5A), leading to the postulation that
MDM2 may play a role in maintaining low levels of p53cation stems from the presence in HeLa cells of HPV-
16 E6 protein, which can utilize the cellular proteolytic in normal cells as well as in removing p53 during recov-
ery from stress-induced arrest through a feedback regu-system to target p53 for ubiquitin-dependent degrada-
tion (Scheffner et al., 1990, 1993). Although there is no latory loop. While it is tempting to speculate that ARF
may be activated by stress to cause MDM2 degradationevidence that E6 could have a similar effect on the stabil-
ity of MDM2, we cannot firmly exclude the possibility and p53 accumulation, it has been observed that induc-
tion of p53 and p21 by g irradiation does not dependthat E6 may have contributed to ARF-promoted MDM2
degradation through an as yet unknown mechanism. on ARF (Kamijo et al., 1997). This indicates that, at least
in the case of DNA double-strand breaks produced bySeveral observations, however, argue against such a
possibility. First, binding of ARF to MDM2 does not re- g irradiation, ARF plays at most a redundant, if not a
minor, role in mediating p53 accumulation. Therefore,quire any other protein, and expression of E6 in HeLa
cells does not disrupt this interaction. Second, E6 tar- as with INK4a, elucidating the cellular signals that regu-
late the level or activity of ARF remains a major chal-gets p53 for degradation by promoting the interaction





Exon 1b of human ARF was amplified from human placental cDNA by
polymerase chain reaction (PCR) using the following oligonucleotide
primers based on published human ARF sequence (Duro et al., 1995;
Mao et al., 1995; Stone et al., 1995): E1S (sense) 59-GGAATTCCCAT
GGTGCGCAGGTTCTTGGTGACC-39 and E1A (antisense) 59-CATCA
TCATGACCTGGTCTTCTAGGAAGCGGCTGCT-39. EcoRI and NcoI
restriction sites were incorporated into the sense primer (underlined)
to facilitate subsequent cloning. Exons 2 and 3 were PCR amplified
from human INK4a cDNA using the following primers (Serrano et
al., 1993): E2S (sense) 59-CTAGAAGACCAGGTCATGATGATGGGC
AGC-39 and E2A (antisense) 59-CGATGAATTAAGCTTGAGCTCGG-
39 (a natural HindIII site present in the 39 UTR of ARF and INK4a is
underlined). PCR conditions were: 1 mM each oligonucleotide, 2
U Taq polymerase, and 1X PCR buffer (Perkin-Elmer, Roche). For
amplification of exon 2±3, dimethylsulfoxide (DMSO) was added
to a final concentration of 5%. Thirty cycles of amplification were
completed using the following cycling temperatures: denaturation
for 30 s at 958C, annealing for 60 s at 558C for exon 1b or 508C for
exon 2±3, and elongation for 90 s at 728C. The amplified exon 1b
and exon 2-3 were mixed in a 1:1 ratio and reamplified using sense
E1S and antisense E2A primers under the same conditions as for
exon 2 PCR except that the annealing temperature was 458C. The
PCR product containing full-length human ARF coding sequenceFigure 7. INK4a and ARF Pathways
was first subcloned into a GST fusion expressing vector, pGEX-KG,
(A) ARF, via an exon 1b-encoded N-terminal domain, binds to a after restriction with NcoI and HindIII yielding pGEX-ARF, which
C-terminal portion of MDM2 and promotes its degradation (indicated was verified by DNA sequencing. From pGEX-ARF, a series of ARF
by stippled appearance). MDM2 via an N-terminal domain forms a derivative plasmids were constructed by subcloning into pCI-neo
complex with and promotes the degradation of p53. ARF-promoted (Promega) and adding an amino terminal HA epitope±tag into the
MDM2 degradation is also associated with ARF-dependent MDM2 NcoI EcoRI site of pCI-neo or by subcloning into pcDNA3-myc (a
modification, but the significance of this modification in regulating modified pcDNA3 vector that contains a myc epitope tag down-
the degradation of MDM2 is not clear. p53 is also a phosphoprotein, stream of a CMV and a T7 promoter, InVitrogen), to yield pCI-neo-
and phosphorylation of p53 by DNA-dependent proteinkinase (DNA- HA-ARF and pcDNA3-myc-ARF that were used for both in vitro
PK) following DNA damage hinders its interaction with MDM2 (Shieh translation using T7 RNA polymerase and expression in mammalian
et al., 1997). The mdm2 gene itself is activated by p53, creating an cells from the CMV promoter. The HA-ARF fragment was further
autoregulatory feedback loop (Barak et al., 1993, 1994; Wu et al., subcloned from pCI-neo-HA-ARF into the pTRE vector (Clontech,
1993). Palo Alto, CA) that contains a CMV promoter under the control of
(B) Comparison of the ARF-MDM2-p53 pathway and the INK4a± a tetracyclin response element to yield pTRE-HA-ARF, which is
cyclin D/CDK4,6-pRB pathway. The regulation of both ARF and suitable for expression in tetracyclin-inducible HeLa cells (HeLa-
INK4a is not known. tet off, Clontech). ARF deletion mutants were constructed by PCR
using pcDNA3-myc-ARF as a template. The two pairs of primers
used were as follows: 59-TAATACGACTCACTATAGGG-39 (sense, a
T7 primer) and 59-TTACTCGAGTCATGGTCTTCTAGGAAGCGGCTGOur finding that ARF stabilizes p53 by promoting the
CTG-39 (antisense, a XhoI site incorporated for subsequent subclon-degradation of MDM2reveals a tumor suppressionpath-
ing, is underlined) to generate a fragment corresponding to theway that involves two tumor suppressors, ARF and p53, N-terminal 64 amino acids encoded by exon 1b; 59-ATAGAATTCGG
both of which are frequently inactivated in many types TCATGATGATGGGCAGCGC-39 (sense, an EcoRI site is underlined)
of human cancers, and a proto-oncogene, mdm2, that and E2A (antisense) to generate a fragment corresponding to
the C-terminal 68 residues lacking exon 1b. Both PCR productsis genomically amplified with high frequency in human
were cloned into pcDNA3-myc to yield pcDNA3-myc-ARF(N) andsarcomas (Figure 7A). There is a striking similarity be-
pcDNA3-myc-ARF(C), respectively. All ARF plasmids were con-tween this pathway and another major tumor suppres-
firmed by direct sequencing of isolated plasmids.
sion pathway (Figure 7B) INK4a±cyclin D1/CDK4-pRB
that similarly includes two frequently mutated tumor Yeast Two-Hybrid Assay
The cDNA sequence encoding full-length human ARF was clonedsuppressors, INK4a and pRB, and a proto-oncogene,
into pGBT8, a modified version of pGBT9, in frame with the DNA-cyclin D1, which is amplified in several types of human
binding domain of Gal4.This constructwas cotransformedinto HF7ccancers (Lammie and Peters, 1991; Hunter and Pines,
yeast with a HeLa cDNA library cloned into pGADGH (Clontech) as
1994; Sherr, 1996). Amusingly, both pathways involve previously described (Guan et al., 1994). An estimated 2.1 3 106
two steps of negative regulation that transduce signals transformants were screened. Yeast containing interacting proteins
was identified by growth on media lacking leucine, tryptophan, andas stop-go-stop for the cell cycle. Cancer-associated
histidine and confirmed by assaying for b-galactosidase activity.point mutations in the ARF-INK4a locus have so far been
Plasmids were rescued from positive yeast colonies and confirmedfound to preferentially, if not exclusively, impinge on
by cotransforming into HF7c cells with pGBT8-ARF and testing their
INK4a (Quelle et al., 1997). No point mutations within growth on the selection media (2LWH) with and without 5 mM
ARF's exon 1b have been detected in primary tumors 3-aminotriazole (3-AT). The cDNA insert of rescued plasmids was
determined by DNA sequencing.or tumor-derived cell lines. Therefore, point mutations
and biallelic deletions are functionally distinct and may
Cell Culture, Transfection, and FACS Analysishave been selectively targeted during tumor develop-
All cells, unless otherwise specified, were obtained from the ATCC.
ment: while the INK4a mutations selectively inactivate HeLa Tet-Off cells were obtained from Clontech. All cells were cul-
the Rb pathway, the deletion of the ARF-INK4a locus tured in a 378C incubator with 5% CO2 in Dulbecco's modified Ea-
gle's medium (DMEM) supplemented with 10% fetal bovine serumimpairs both Rb and p53 pathways.
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(FBS). Cell transfections were carried out using the LipofectAMINE buffer (Jenkins and Xiong, 1995) was added to each binding reaction
followed by immunoprecipitation with appropriate antibodies.reagent according to the manufacturer's instructions (GIBCO-BRL).
Cells were plated at a low density (approximately 3 3 105 cell/100
mm dish or 1 3 105 cells/60 mm dish) and allowed to grow to Acknowledgments
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